-
Patent Agency Ranking
公开(公告)号：KR1020090075637A
公开(公告)日：2009-07-08
申请号：KR1020090000331
申请日：2009-01-05
Applicant: 재단법인서울대학교산학협력재단
IPC: A01K67/027 , C12N15/09
CPC classification number: A01K67/0275 , A01K2227/10 , C07K14/43595 , C12N15/873
Abstract: A method of manufacturing a cloned dog is provided, which uses transfection and targeting technology of the desired gene. A method of manufacturing a cloned dog comprises: a step for producing the donor nucleus cell from the somatic cell line picked from the dog and expressing by introducing the DNA structure containing the target gene; a step for adding the cell cycle synchronization inducing agent and cultivating; a step for producing the nuclear transfer embryo by transplanting the cultivated donor nucleus cell to the denucleated dog recipient; a step for activating; and a step for producing a litter.
Abstract translation: 提供了制造克隆狗的方法，其使用所需基因的转染和靶向技术。 制造克隆狗的方法包括：从从狗取出的体细胞系中产生供体核细胞并通过引入含有靶基因的DNA结构进行表达的步骤; 添加细胞周期同步诱导剂并培养的步骤; 通过将培养的供体核细胞移植到去核的狗接受者来生产核转移胚的步骤; 激活的一个步骤 以及生产垃圾的步骤。
-
公开(公告)号：KR100525786B1
公开(公告)日：2005-11-03
申请号：KR1020040017738
申请日：2004-03-16
Applicant: 재단법인서울대학교산학협력재단 , 알앤엘생명과학주식회사
IPC: A61K36/484 , A61P35/00
Abstract: 본 발명은 에스트로젠 활성 및 암 세포에 대한 증식 억제 활성을 나타내는 감초(
Glycyrrhiza uralensis Fisch) 추출물 또는 이솔리퀴리틴(isoliquiritin)을 유효성분으로 하는 파이토에스트로젠(phytoestrogen) 조성물에 관한 것으로, 본 발명의 감초 추출물 또는 이솔리퀴리틴은 에스트로젠성은 나타내나 안드로젠성은 나타내지 않고, 내분비계 장애물질인 비스페놀-A의 활성을 억제하며, 유방암 세포를 비롯한 암 세포의 증식을 저해하므로, 파이토에스트로젠으로서 호르몬 대체 치료 및 유방암의 예방 및 치료를 위해 사용될 수 있다.-
3.发明公开
公开(公告)号：KR1020040082951A
公开(公告)日：2004-09-30
申请号：KR1020040017738
申请日：2004-03-16
Applicant: 재단법인서울대학교산학협력재단 , 알앤엘생명과학주식회사
IPC: A61K36/484 , A61P35/00
CPC classification number: A61K36/484 , A23V2200/308 , A61K2236/33
Abstract: PURPOSE: A phytoestrogenic composition containing a Glycyrrhizae Radix extract or isoliquiritin having potent phytoestrogenic activity is provided. The composition exhibits phytoestrogenic properties, inhibits the activity of bisphenol A as an endocrine disrupting substance and suppresses proliferation of cancer cells including breast cancer cells and is thus used for hormone replacement therapy and prevention and treatment of breast cancer. CONSTITUTION: The phytoestrogenic composition contains a Glycyrrhizae Radix extract or isoliquiritin as an effective ingredient and is used for prevention and treatment of osteoporosis, cardiac and circulatory disorders, menopause symptoms or cancer. The Glycyrrhizae Radix extract is prepared by extracting in an organic solvent selected from the group consisting of C1-4 alcohol, C1-4 aqueous alcohol solution, ethyl acetate, trichloromethyl and hexane. The C1-4 alcohol is methanol or ethanol. A food composition for treatment of the symptoms of menopause and prevention of cancer contains 0.1 to 50% by weight of the organic solvent extract of Glycyrrhizae Radix extract, based on the total weight of the food composition.
Abstract translation: 目的：提供含有甘草提取物或具有强烈植物雌激素活性的异喹啉的植物雌激素组合物。 该组合物具有植物雌激素特性，抑制双酚A作为内分泌干扰物质的活性，抑制包括乳腺癌细胞在内的癌细胞的增殖，因此用于激素替代治疗和预防和治疗乳腺癌。 构成：植物雌激素组合物含有甘草提取物或异喹啉作为有效成分，用于预防和治疗骨质疏松症，心脏和循环系统疾病，绝经症状或癌症。 甘草提取物通过在选自C 1-4醇，C 1-4醇水溶液，乙酸乙酯，三氯甲基和己烷的有机溶剂中萃取来制备。 C 1-4醇是甲醇或乙醇。 基于食物组合物的总重量，用于治疗更年期症状和预防癌症的食物组合物含有甘草提取物的有机溶剂提取物的0.1-50重量％。
-
公开(公告)号：KR101105248B1
公开(公告)日：2012-01-17
申请号：KR1020090000331
申请日：2009-01-05
Applicant: 재단법인서울대학교산학협력재단
IPC: A01K67/027 , C12N15/09
CPC classification number: A01K67/0275 , A01K2227/10 , C07K14/43595 , C12N15/873
Abstract: 본 발명은 형질전환 복제개의 생산방법에 관한 것으로, 보다 구체적으로는 개의 난자로부터 핵을 제거하여 탈핵 난자를 제조하고 상기 탈핵 난자에 목적 유전자로 형질전환시킨 세포를 이식하여 핵 이식란을 제조한 다음, 이를 대리모에 이식하는 것을 특징으로 하는, 목적 유전자가 도입된 복제개의 생산방법에 관한 것이다. 본 발명은 외래성 유전자의 성공적 도입에 의해 질환모델 동물의 대량 생산가능성을 확인하였으며, 이는 우량 품종의 번식, 이종이식, 질환 모델동물 등 수의학, 인류학 및 의학연구 분야에 유용하다.
형질전환복제개, 로스코비틴, RFP 유전자-
公开(公告)号：KR1020080101140A
公开(公告)日：2008-11-21
申请号：KR1020070047472
申请日：2007-05-16
Applicant: 주식회사 알바이오 , 재단법인서울대학교산학협력재단
Abstract: A pharmaceutical composition is provided to replace damaged liver cells using mesenchymal stem cell, to recover function of the liver and to prevent and treat a liver fibrosis or a liver sclerosis by reducing collagen fiber deposited in the liver. A composition for preventing and treating a liver fibrosis or a liver sclerosis includes mesenchymal stem cell originated from an umbilical cord blood or a fatty tissue. The umbilical cord blood or the fatty tissue is separated from human. A pharmaceutical composition for preventing and treating the liver fibrosis or the liver sclerosis includes the mesenchymal stem cell originated from the umbilical cord blood or the fatty tissue. The umbilical cord blood or the fatty tissue is separated from human.
Abstract translation: 提供药物组合物以使用间充质干细胞代替损伤的肝细胞，通过减少沉积在肝脏中的胶原纤维来恢复肝脏的功能并预防和治疗肝纤维化或肝硬化。 用于预防和治疗肝纤维化或肝硬化的组合物包括起源于脐带血或脂肪组织的间充质干细胞。 脐带血或脂肪组织与人分离。 用于预防和治疗肝纤维化或肝硬化的药物组合物包括起源于脐带血或脂肪组织的间充质干细胞。 脐带血或脂肪组织与人分离。
-
-
-
-
Search Results
5
records
(took 0.019 seconds)
